10 High-Flying Penny Stocks to Buy

​7. OPKO Health, Inc. (NASDAQ:OPK)

Number of Hedge Fund Holders: 16

OPKO Health, Inc. (NASDAQ:OPK) is one of the High-Flying Penny Stocks to Buy. On March 12, Barrington lowered the firm’s price target on OPKO Health, Inc. (NASDAQ:OPK) from $2.25 to $1.50 and maintained a Buy rating on the stock.

​The firm noted that although the company topped Street estimates for fiscal Q4 2025, the way it achieved the results is concerning. The firm highlighted that “other revenue largely saved the quarter, but this level of performance is not sustainable.”

The company reported fiscal Q4 2025 earnings on February 26. The revenue for the quarter declined 19.12% year-over-year to $148.5 million but topped consensus by $8.74 million. The EPS came in at negative $0.04 but exceeded expectations by $0.03.

​Management noted that the diagnostic revenue for the quarter was $71.1 million, down from $103.1 million a year ago. The decrease was mainly due to the sale of some BioReference assets in 2025 and the resulting decline in clinical test volumes. This was slightly offset by the increased demand and higher average reimbursement for the 4Kscore test.

​Looking ahead, OPKO Health, Inc. (NASDAQ:OPK) expects fiscal first quarter 2026 revenue in the range of $125 million to $140 million, while the full-year revenue is expected in the range of $530 million to $560 million.

​OPKO Health, Inc. (NASDAQ:OPK) is a multinational biopharmaceutical and diagnostics company operating in pharmaceuticals and clinical lab services. Its pharmaceutical segment develops treatments like NGENLA (once-weekly growth hormone) and Rayaldee for kidney disease-related hyperparathyroidism, across global markets including the US and Latin America.